[1] Zhao Y, Wei L, Dou ZH, Zhao DC, Gan XM, Wu YS, et al. Changing mortality and patterns of death causes in HIV infected patients — China, 2013-2022. China CDC Wkly 2023;5(48):1073 − 8. https://doi.org/10.46234/ccdcw2023.201CrossRef
[2] Zhang FJ, Zhao Y, Ma Y, Zhao DC, Dou ZH, Wu YS, et al. Progress and achievements of free antiretroviral treatment for AIDS in China. Chin J AIDS STD 2022;28(1):6-9. http://dx.doi.org/10.13419/j.cnki.aids.2022.01.02. (In Chinese). 
[3] Lai SH, Chen J, Celentano D, Page JB, Lai H, Yang JY, et al. Adoption of injection practices in heroin users in Guangxi Province, China. J Psychoact Drugs 2000;32(3):285 − 92. https://doi.org/10.1080/02791072.2000.10400451CrossRef
[4] Zhang LF, Qiao XC, Nie XY, Guo XL, Mei ZQ. A retrospective cohort study on the survival of blood-borne human immunodeficiency virus cases in a county, China. Chin J Epidemiol 2004;25(11):941 − 4. https://doi.org/10.3760/j.issn:0254-6450.2004.11.006CrossRef
[5] Ke SS, Fang Q, Lan JG, Qiao NN, Zhang XH, Xie CP, et al. Survival times of HIV/AIDS in different AIDS diagnostic and treatment guidelines from 2006 to 2020 in Liuzhou, China. BMC Public Health 2023;23(1):1745. https://doi.org/10.1186/s12889-023-15662-3CrossRef
[6] Manosuthi W, Charoenpong L, Santiwarangkana C. A retrospective study of survival and risk factors for mortality among people living with HIV who received antiretroviral treatment in a resource-limited setting. AIDS Res Ther 2021;18(1):71. https://doi.org/10.1186/s12981-021-00397-1CrossRef
[7] Park B, Choi Y, Kim JH, Seong H, Kim YJ, Lee M, et al. Mortality and causes of death among individuals diagnosed with human immunodeficiency virus in Korea, 2004-2018: an analysis of a nationwide population-based claims database. Int J Environ Res Public Health 2022;19(18):11788. https://doi.org/10.3390/ijerph191811788CrossRef
[8] Tsuda H, Koga M, Nojima M, Senkoji T, Kubota M, Kikuchi T, et al. Changes in survival and causes of death among people living with HIV: three decades of surveys from Tokyo, one of the Asian metropolitan cities. J Infect Chemother 2021;27(7):949 − 56. https://doi.org/10.1016/j.jiac.2021.02.003CrossRef
[9] Braunstein SL, Kersanske L, Torian LV, Lazar R, Harriman G. survival among new yorkers with HIV from 1981 to 2017: inequities by race/ethnicity and transmission risk persist into the post-HAART era. AIDS Behav 2022;26(1):284 − 93. https://doi.org/10.1007/s10461-021-03382-xCrossRef
[10] Castillo-Rozas G, Tu SX, Luz PM, Mejia F, Sierra-Madero J, Rouzier V, et al. Clinical outcomes and risk factors for immune recovery and all-cause mortality in Latin Americans living with HIV with virological success: a retrospective cohort study. J Int AIDS Soc 2024;27(3):e26214. https://doi.org/10.1002/jia2.26214CrossRef
[11] Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, et al. Morbidity and aging in HIV-infected persons: the swiss HIV cohort study. Clin Infect Dis 2011;53(11):1130 − 9. https://doi.org/10.1093/cid/cir626CrossRef
[12] Godfrey C, Vallabhaneni S, Shah MP, Grimsrud A. Providing differentiated service delivery to the ageing population of people living with HIV. J Int AIDS Soc 2022;25 Suppl 4(Suppl 4):e26002. http://dx.doi.org/10.1002/jia2.26002.
[13] Zhang XJ, Wang N, Vermund SH, Zou HC, Li XH, Zhang FJ, et al. Interventions to improve the HIV continuum of care in China. Curr HIV/AIDS Rep 2019;16(6):448 − 57. https://doi.org/10.1007/s11904-019-00469-yCrossRef
[14] Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009;360(18):1815 − 26. https://doi.org/10.1056/NEJMoa0807252CrossRef
[15] Kamya MR, Petersen ML, Kabami J, Ayieko J, Kwariisima D, Sang N, et al. SEARCH human immunodeficiency virus (HIV) streamlined treatment intervention reduces mortality at a population level in men with low CD4 counts. Clin Infect Dis 2021;73(7):e1938 − 45. https://doi.org/10.1093/cid/ciaa1782CrossRef